145 related articles for article (PubMed ID: 22394323)
1. Identification of suitable formulations for high dose oral studies in rats using in vitro solubility measurements, the maximum absorbable dose model, and historical data sets.
Wuelfing WP; Kwong E; Higgins J
Mol Pharm; 2012 May; 9(5):1163-74. PubMed ID: 22394323
[TBL] [Abstract][Full Text] [Related]
2. Preclinical dose number and its application in understanding drug absorption risk and formulation design for preclinical species.
Wuelfing WP; Daublain P; Kesisoglou F; Templeton A; McGregor C
Mol Pharm; 2015 Apr; 12(4):1031-9. PubMed ID: 25671350
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.
Crivori P; Morelli A; Pezzetta D; Rocchetti M; Poggesi I
Eur J Pharm Sci; 2007 Nov; 32(3):169-81. PubMed ID: 17714921
[TBL] [Abstract][Full Text] [Related]
4. High drug loading self-microemulsifying/micelle formulation: design by high-throughput formulation screening system and in vivo evaluation.
Sakai K; Obata K; Yoshikawa M; Takano R; Shibata M; Maeda H; Mizutani A; Terada K
Drug Dev Ind Pharm; 2012 Oct; 38(10):1254-61. PubMed ID: 22339057
[TBL] [Abstract][Full Text] [Related]
5. Striking the Optimal Solubility-Permeability Balance in Oral Formulation Development for Lipophilic Drugs: Maximizing Carbamazepine Blood Levels.
Beig A; Miller JM; Lindley D; Dahan A
Mol Pharm; 2017 Jan; 14(1):319-327. PubMed ID: 27981848
[TBL] [Abstract][Full Text] [Related]
6. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
7. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
[TBL] [Abstract][Full Text] [Related]
8. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
Gao Y; Carr RA; Spence JK; Wang WW; Turner TM; Lipari JM; Miller JM
Mol Pharm; 2010 Oct; 7(5):1516-26. PubMed ID: 20715778
[TBL] [Abstract][Full Text] [Related]
9. Developability assessment of clinical drug products with maximum absorbable doses.
Ding X; Rose JP; Van Gelder J
Int J Pharm; 2012 May; 427(2):260-9. PubMed ID: 22349050
[TBL] [Abstract][Full Text] [Related]
10. Integrating drug permeability with dissolution profile to develop IVIVC.
Takano R; Kataoka M; Yamashita S
Biopharm Drug Dispos; 2012 Oct; 33(7):354-65. PubMed ID: 22581486
[TBL] [Abstract][Full Text] [Related]
11. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
[TBL] [Abstract][Full Text] [Related]
12. Fraction of a dose absorbed estimation for structurally diverse low solubility compounds.
Sugano K
Int J Pharm; 2011 Feb; 405(1-2):79-89. PubMed ID: 21134428
[TBL] [Abstract][Full Text] [Related]
13. The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations.
Miller JM; Beig A; Carr RA; Webster GK; Dahan A
Mol Pharm; 2012 Mar; 9(3):581-90. PubMed ID: 22280478
[TBL] [Abstract][Full Text] [Related]
14. Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation.
Dai WG; Pollock-Dove C; Dong LC; Li S
Adv Drug Deliv Rev; 2008 Mar; 60(6):657-72. PubMed ID: 18222563
[TBL] [Abstract][Full Text] [Related]
15. Parallel screening approach to identify solubility-enhancing formulations for improved bioavailability of a poorly water-soluble compound using milligram quantities of material.
Dai WG; Dong LC; Li S; Pollock-Dove C; Chen J; Mansky P; Eichenbaum G
Int J Pharm; 2007 May; 336(1):1-11. PubMed ID: 17178444
[TBL] [Abstract][Full Text] [Related]
16. Selection of oral bioavailability enhancing formulations during drug discovery.
Zheng W; Jain A; Papoutsakis D; Dannenfelser RM; Panicucci R; Garad S
Drug Dev Ind Pharm; 2012 Feb; 38(2):235-47. PubMed ID: 21851310
[TBL] [Abstract][Full Text] [Related]
17. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
O'Driscoll CM; Griffin BT
Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
[TBL] [Abstract][Full Text] [Related]
18. Prediction of human pharmacokinetics--gastrointestinal absorption.
Fagerholm U
J Pharm Pharmacol; 2007 Jul; 59(7):905-16. PubMed ID: 17637184
[TBL] [Abstract][Full Text] [Related]
19. Development of ALZET® osmotic pump compatible solvent compositions to solubilize poorly soluble compounds for preclinical studies.
Gullapalli R; Wong A; Brigham E; Kwong G; Wadsworth A; Willits C; Quinn K; Goldbach E; Samant B
Drug Deliv; 2012; 19(5):239-46. PubMed ID: 22656673
[TBL] [Abstract][Full Text] [Related]
20. Oral delivery of highly lipophilic poorly water-soluble drugs: spray-dried dispersions to improve oral absorption and enable high-dose toxicology studies of a P2Y1 antagonist.
Chen XQ; Stefanski K; Shen H; Huang C; Caporuscio C; Yang W; Lam P; Su C; Gudmundsson O; Hageman M
J Pharm Sci; 2014 Dec; 103(12):3924-3931. PubMed ID: 25308627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
